Author | Emily Wynja, MSIV


A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue

October 17, 2018

Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.